Effective use of everolimus as salvage chemotherapy for ovarian clear cell carcinoma: a case report

Abstract

Eriko Takatori, Tadahiro Shoji, Yuki Miura, Anna Takada, Satoshi Takeuchi, Toru SugiyamaDepartment of Obstetrics and Gynecology, Iwate Medical University School of Medicine, Morioka, Japan Abstract: A case study using mammalian target of rapamycin complex 1 in recurrent ovarian clear cell carcinoma (CCC) was recently conducted. We report our experience with a patient suffering from recurrent ovarian CCC who achieved long-term disease control with everolimus administration. The patient was a 53-year-old woman who was diagnosed with recurrent ovarian CCC with dissemination throughout the abdominal cavity. Previously, she had received three chemotherapy regimens, but the disease was progressive and she showed no response to treatment. Therefore, oral everolimus administration (everolimus 10 mg/day on days 1–28, a 28-day period comprised one cycle) was started. She was administered six cycles. The antitumor response was stable disease, and grade 3 anemia was observed. Chemotherapy was then switched to gemcitabine/docetaxel therapy. In the middle of the second cycle, a rapid increase in ascitic fluid and CA125 elevation were observed. Thereafter, the patient received best supportive care and died of the disease. Everolimus may inhibit malignant progression of ovarian CCC. Keywords: mTORC1, ovarian cancer, palliative chemotherapy